Evotec AG announced today that its multi-target endometriosis alliance with Bayer has reached another significant pre-clinical milestone, triggering a payment of approx. EUR 5 m to Evotec for the transition of a programme into pre-clinical development for the treatment of endometriosis. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-pre-clinical-milestone-as-part-of-its-endometriosis-alliance-with-bayer-5460